Addex Therapeutics Ltd (SWX:ADXN)
Switzerland
· Delayed Price · Currency is CHF
0.0450
-0.0050 (-10.00%)
Mar 9, 2026, 5:31 PM CET
Addex Therapeutics Ratios and Metrics
Market cap in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 5 | 6 | 6 | 10 | 39 | 53 | |
| Market Cap Growth | -11.08% | -9.01% | -40.48% | -73.65% | -25.96% | 22.57% | |
| Enterprise Value | 3 | 2 | 2 | 0 | 24 | 36 | |
| Last Close Price | 0.04 | 0.06 | 0.05 | 0.10 | 1.04 | 1.99 | |
| PE Ratio | - | 0.80 | - | - | - | - | |
| PS Ratio | 33.09 | 13.72 | 3.82 | 7.19 | 12.50 | 13.73 | |
| PB Ratio | 0.88 | 0.58 | 5.40 | 2.11 | 2.33 | 3.64 | |
| P/TBV Ratio | 0.88 | 0.58 | 5.40 | 2.11 | 2.33 | 3.64 | |
| EV/Sales Ratio | 19.52 | 5.66 | 1.08 | 0.28 | 7.76 | 9.20 | |
| Debt / Equity Ratio | 0.01 | 0.00 | 0.30 | 0.08 | 0.03 | 0.04 | |
| Net Debt / Equity Ratio | -0.36 | -0.34 | -3.07 | -1.34 | -1.18 | -1.24 | |
| Net Debt / EBITDA Ratio | 0.88 | 1.29 | 1.58 | 0.63 | 1.32 | 1.53 | |
| Net Debt / FCF Ratio | 1.37 | 0.61 | 0.44 | 0.40 | 1.36 | 1.48 | |
| Asset Turnover | 0.02 | 0.05 | 0.25 | 0.09 | 0.15 | 0.15 | |
| Quick Ratio | 1.91 | 4.19 | 1.39 | 2.30 | 5.03 | 5.18 | |
| Current Ratio | 2.01 | 4.42 | 1.46 | 2.38 | 5.31 | 5.38 | |
| Return on Equity (ROE) | -72.84% | -90.72% | -82.53% | -98.92% | -97.35% | -64.08% | |
| Return on Assets (ROA) | -15.90% | -22.48% | -21.69% | -42.75% | -45.37% | -28.76% | |
| Return on Capital Employed (ROCE) | -40.30% | -27.90% | -128.30% | -210.80% | -84.20% | -73.90% | |
| Earnings Yield | -116.23% | 125.46% | -170.78% | -200.32% | -38.95% | -24.15% | |
| FCF Yield | - | -95.57% | -129.41% | -158.28% | -37.39% | -22.99% | |
| Buyback Yield / Dilution | -7.75% | -32.04% | -64.45% | -32.43% | -27.88% | -0.96% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.